Animal Antibiotics and Antimicrobials Global Market Report 2024

Animal antibiotics and antimicrobials refer to veterinary medications designed to combat bacteria or microorganisms by either killing them or limiting their growth and multiplication. These medications serve various purposes in animals, including the treatment of clinical diseases, prevention or control of common disease events, and the enhancement of animal growth.

The main types of animal antibiotics and antimicrobials encompass tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobials and antibiotics. Tetracyclines, for example, are bacteriostatic and function by reversibly binding to bacterial 30S ribosomes, thereby altering the bacterial cytoplasmic membrane. Tetracyclines are administered in various forms, including premixes, oral powder, oral solutions, and injections. These medications find use in both companion and food-producing animals.

The animal antibiotics and antimicrobials market research report is one of a series of new reports that provides animal antibiotics and antimicrobials market statistics, including animal antibiotics and antimicrobials industry global market size, regional shares, competitors with a animal antibiotics and antimicrobials market share, detailed animal antibiotics and antimicrobials market segments, market trends and opportunities, and any further data you may need to thrive in the animal antibiotics and antimicrobials industry. This animal antibiotics and antimicrobials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The animal antibiotics and antimicrobials market size has grown strongly in recent years. It will grow from $4.97 billion in 2023 to $5.34 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The observed growth in the historical period can be attributed to various factors, including disease outbreaks in animals, growth in livestock production, regulatory policies influencing the use of antibiotics and antimicrobials in animals, and increased consumer awareness about the importance of animal health.

The animal antibiotics and antimicrobials market size is expected to see strong growth in the next few years. It will grow to $7.08 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be attributed to factors such as the emergence of new diseases, global population growth, regulatory changes impacting the use of antibiotics and antimicrobials in animals, and increasing public health concerns related to animal health. Key trends expected in the forecast period include the exploration of alternative solutions, collaborative initiatives among stakeholders, the development of customized treatment plans, increased investments in research, and the integration of blockchain technology for enhanced traceability and transparency in the use of animal antibiotics and antimicrobials.

The surge in demand for animal-based food products is propelling the expansion of the market for animal antibiotics and antimicrobials. Food items derived from animals, such as milk, eggs, and meat, serve as significant sources of nutrition and hold a crucial place in the human diet. Entities engaged in the production of these animal-based food products are prioritizing the development of healthy or disease-resistant animal herds by employing animal antibiotics and antimicrobials preventatively. For instance, as per data revealed in the Packaged Facts report on Global Meat & Poultry trends, global consumption of meat and poultry is projected to reach 313 million metric tons in 2023, experiencing an annual growth rate of 1.4%. Consequently, the escalating demand for animal-derived food products is anticipated to drive the need for animal antibiotics and antimicrobials throughout the forecast period.

The anticipated rise in zoonotic diseases is set to further fuel the growth of the animal antibiotics and antimicrobials market. Zoonotic diseases encompass infections caused by microscopic organisms, infections, and parasites that are transmissible between animals and humans. Antibiotics and antimicrobials play a vital role in treating these diseases, which can be transmitted from animals to humans. Various pathogens, including bacteria, viruses, fungi, and parasites, are responsible for these diseases. Well-documented examples of zoonotic diseases comprise anthrax, bovine tuberculosis, brucellosis, and hemorrhagic colitis. For instance, according to a FoodNet study conducted by the Centers for Disease Control and Prevention in the USA, there were 25,479 reported cases of infection, leading to 5,981 hospitalizations and 170 deaths due to zoonotic diseases in 2022. Consequently, the upsurge in zoonotic diseases is expected to be a driving factor for the animal antibiotics and antimicrobials market in the foreseeable future.

A prominent trend gaining traction in the animal antibiotics and antimicrobials market is strategic partnerships. Companies operating in this sector are forging strategic alliances with pertinent industry players to facilitate research and development in innovative animal antibiotics and antimicrobials. In May 2022, Gnubiotics Sciences, a biotechnology company based in Switzerland dedicated to addressing microbiome-related health conditions in humans and animals, established a partnership with ADM, a US-based developer of human and health nutrition solutions, aimed at commercializing new microbiome solutions targeting companion animal health and wellbeing.

Prominent companies within the animal antibiotics and antimicrobials sector are intensifying their efforts towards introducing early detection tests in animals as a means to secure a competitive advantage in the market. These tests serve diverse purposes, including detecting minimal residual diseases, monitoring recurrence and treatment responses, and aiding in targeted treatment selection. This broadens the scope of tools available to veterinarians for effectively managing animal diseases. For instance, in May 2021, PetDx, a molecular diagnostics company situated in the United States, unveiled OncoK9, an innovative multi-cancer early detection test tailored for dogs. OncoK9 is engineered to assist veterinarians in identifying cancer in dogs at an earlier stage through a simple blood draw. The test utilizes next-generation sequencing (NGS) technology and proprietary antimicrobial algorithms to identify genomic alterations associated with cancer in DNA extracted from whole blood samples of canines.

In July 2022, Dechra Pharmaceuticals, a UK-based pharmaceutical enterprise specializing in animal medicines, completed the acquisition of Piedmont Animal Health for $210 million in cash. This acquisition aligns with Dechra's strategic vision to enhance its pipeline of companion animal pharmaceutical products and expand its team of specialized experts in pharmaceutical research and development, primarily situated in Greensboro. Piedmont Animal Health, based in the United States, is a company dedicated to veterinary pharmaceuticals for companion animals.

Major companies operating in the in the animal antibiotics and antimicrobials market report are C. H. Boehringer Sohn AG & Co. KG, Zoetis Inc., Elanco Animal Health Inc., Merck & Co. Inc., Phibro Animal Health Corp., Ashish Life Science Pvt. Limited, Ayurvet Limited, Dechra Pharmaceuticals Plc, Endovac Animal Health, HIPRA S. A., Huvepharma Inc., Inovet (V. M. D. nv/sa), Kyoritsu seiyaku Corporation, Lutim Pharma Private Limited, Neogen Corporation, Tianjin Ringpu Bio-Technology Co. Ltd., UCBVET Animal Health, Vetoquinol, Virbac, Zydus Animal Health Limited, China Animal Husbandry Co. Ltd., ECO Animal Health Ltd., Nicosia International, Norbrook Laboratories Limited, Biovet AD - Peshtera, BioChek B. V., Bio Agri Mix LP, Bio-Medical Research Ltd., Bioiberica S. A. U., Ceva Santé Animale

North America was the largest region in the animal antibiotics and antimicrobials market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the animal antibiotics and antimicrobials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The animal antibiotics and antimicrobials market consists of sales of glycopeptides, ß-Lactam antibiotics, and polymixins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.